ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,302.85
      0.11%
      US Tech 100
      18,107.20
      0.15%
      Dow Jones
      39,902.05
      0.08%
      Brent Oil
      83.285
      0.10%
      Bitcoin
      66,446.88
      1.85%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Innate Pharma SA (IPHA)

      7. Innate Pharma SA (IPHA) News

      IPHA

      Innate Pharma (IPHA)

      Innate Pharma SA
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:IPHA
      DateTimeSourceHeadlineSymbolCompany
      05/15/20246:01AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPHAInnate Pharma SA
      05/15/20241:00AMBusiness WireInnate Pharma partage les abstracts sélectionnés pour le congrès 2024 de l’EHANASDAQ:IPHAInnate Pharma SA
      05/15/20241:00AMBusiness WireInnate Pharma Highlights Abstracts Selected for EHA 2024 CongressNASDAQ:IPHAInnate Pharma SA
      05/14/20241:00AMBusiness WireInnate Pharma Reports First Quarter 2024 Business Update and Financial ResultsNASDAQ:IPHAInnate Pharma SA
      05/14/20241:00AMBusiness WireInnate Pharma fait le point sur ses activités et publie ses résultats financiers pour le premier trimestre 2024NASDAQ:IPHAInnate Pharma SA
      05/07/20241:00AMBusiness WireInnate Pharma organise une conférence téléphonique pour présenter ses résultats au premier trimestre 2024NASDAQ:IPHAInnate Pharma SA
      05/07/20241:00AMBusiness WireInnate Pharma Announces Conference Call and Webcast for Q1 2024 Business UpdateNASDAQ:IPHAInnate Pharma SA
      04/15/20241:00AMBusiness WireInnate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024NASDAQ:IPHAInnate Pharma SA
      04/15/20241:00AMBusiness WireInnate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer PatientsNASDAQ:IPHAInnate Pharma SA
      04/15/20241:00AMBusiness WireL’Assemblée Générale d’Innate Pharma aura lieu le 23 mai 2024NASDAQ:IPHAInnate Pharma SA
      04/15/20241:00AMBusiness WireInnate Pharma annonce la progression de l’essai clinique évaluant le NK Cell Engager SAR443579 / IPH6101 développé par Sanofi vers la Phase 2 dans divers cancers du sangNASDAQ:IPHAInnate Pharma SA
      04/10/20241:00AMBusiness WireInnate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug ConjugateNASDAQ:IPHAInnate Pharma SA
      04/10/20241:00AMBusiness WireInnate Pharma présente des données d’efficacité précliniques pour IPH45, son conjugué anticorps-médicament innovant ciblant nectine-4 a l’AACR 2024NASDAQ:IPHAInnate Pharma SA
      04/09/20241:00AMBusiness WireInnate Pharma annonce sa participation à une prochaine Conférence InvestisseursNASDAQ:IPHAInnate Pharma SA
      04/09/20241:00AMBusiness WireInnate Pharma Announces Its Participation in Upcoming Investor ConferenceNASDAQ:IPHAInnate Pharma SA
      04/05/20243:34AMBusiness WireInnate Pharma Files Its 2023 Universal Registration Document (Document d’enregistrement Universel) and 2023 Annual Report on Form 20-FNASDAQ:IPHAInnate Pharma SA
      04/05/20243:34AMBusiness WireInnate Pharma publie son Document D’enregistrement Universel 2023 et son Rapport Annuel 2023 sur « Form 20-F »NASDAQ:IPHAInnate Pharma SA
      03/21/20242:00AMBusiness WireInnate Pharma présente ses résultats financiers et l'avancée de son portefeuille pour l'année 2023NASDAQ:IPHAInnate Pharma SA
      03/21/20242:00AMBusiness WireInnate Pharma Reports Full Year 2023 Financial Results and Business UpdateNASDAQ:IPHAInnate Pharma SA
      03/19/20242:00AMBusiness WireInnate Pharma Announces Its Participation to Upcoming Investor ConferenceNASDAQ:IPHAInnate Pharma SA
      03/19/20242:00AMBusiness WireInnate Pharma annonce sa participation à une prochaine conférence investisseursNASDAQ:IPHAInnate Pharma SA
      03/14/20242:00AMBusiness WireInnate Pharma organise une conférence téléphonique et un webcast pour présenter ses résultats financiers 2023NASDAQ:IPHAInnate Pharma SA
      03/14/20242:00AMBusiness WireInnate Pharma Announces Conference Call and Webcast for Full Year 2023 Financial ResultsNASDAQ:IPHAInnate Pharma SA
      03/06/20241:00AMBusiness WireInnate Pharma: First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin’s LymphomaNASDAQ:IPHAInnate Pharma SA
      03/06/20241:00AMBusiness WireINNATE PHARMA: TRAITEMENT DU PREMIER PATIENT DANS L’ESSAI DE PHASE 1/2 EVALUANT IPH6501 DANS LES LYMPHOMES NON HODGKINIENS A LYMPHOCYTES B EN RECHUTE ET/OU REFRACTAIRESNASDAQ:IPHAInnate Pharma SA
      03/06/20241:00AMBusiness WireInnate Pharma to Present Nectin-4 Antibody Drug Conjugate IPH45 Preclinical Data at AACR 2024NASDAQ:IPHAInnate Pharma SA
      03/06/20241:00AMBusiness WireInnate Pharma présentera des données précliniques concernant son anticorps conjugué IPH45 ciblant Nectine-4 à l’AACR 2024NASDAQ:IPHAInnate Pharma SA
      02/21/20241:00AMBusiness WireInnate Pharma Announces Its Participation to Upcoming Investor ConferenceNASDAQ:IPHAInnate Pharma SA
      02/21/20241:00AMBusiness WireInnate Pharma annonce sa participation a une prochaine conférence investisseursNASDAQ:IPHAInnate Pharma SA
      01/17/202412:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:IPHAInnate Pharma SA
       Showing the most relevant articles for your search:NASDAQ:IPHA